Theralink And IMAC Holdings Announce Receipt And Response To The Securities And Exchange Commission Comments On The Previously Filed Form S4; Co's Expect To Hear Back From The Securities And Exchange Commission Within The Next 10 Business Days
Portfolio Pulse from Benzinga Newsdesk
Theralink Technologies, Inc. (THER) and IMAC Holdings, Inc. (BACK) have responded to the SEC's comments on their Form S-4, filed for their merger. The companies expect feedback from the SEC within 10 business days. The merger aims to create a proteomics company focused on cancer care and protein analysis, with a robust patent estate, certified lab, and reimbursement agreements, including with Medicare.
November 13, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IMAC Holdings' progress on the merger with Theralink, as indicated by the response to SEC comments, could positively influence its stock in the short term.
IMAC Holdings' involvement in the merger with Theralink and the positive steps towards regulatory approval may boost investor confidence, potentially leading to a short-term uptick in BACK's stock price. The merger's potential to create a significant player in the oncology space is a key factor.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Theralink's response to SEC comments on Form S-4 could advance its merger with IMAC, potentially enhancing its market position in precision oncology.
The news indicates progress in Theralink's merger with IMAC, which could lead to positive investor sentiment and a potential short-term increase in THER's stock price. The merger's focus on creating a leading proteomics company in cancer care is likely to be viewed favorably by the market.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 80